This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nemoto, S.
Right arrow Articles by Lin, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nemoto, S.
Right arrow Articles by Lin, A.

 Previous Article  |  Next Article 

Mol Cell Biol, June 1998, p. 3518-3526, Vol. 18, No. 6
0270-7306/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

Opposing Effects of Jun Kinase and p38 Mitogen-Activated Protein Kinases on Cardiomyocyte Hypertrophy

Shino Nemoto,1 Zelin Sheng,2 and Anning Lin1,*

Department of Pathology, Division of Molecular and Cellular Pathology, University of Alabama at Birmingham, Birmingham, Alabama 35294,1 and Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey 085432

Received 21 October 1997/Returned for modification 9 December 1997/Accepted 26 February 1998

    ABSTRACT
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

c-Jun N-terminal protein kinase (JNK) and p38, two distinct members of the mitogen-activated protein (MAP) kinase family, regulate gene expression in response to various extracellular stimuli, yet their physiological functions are not completely understood. In this report we show that JNK and p38 exerted opposing effects on the development of myocyte hypertrophy, which is an adaptive physiological process characterized by expression of embryonic genes and unique morphological changes. In rat neonatal ventricular myocytes, both JNK and p38 were stimulated by hypertrophic agonists like endothelin-1, phenylephrine, and leukemia inhibitory factor. Expression of MAP kinase kinase 6b (EE), a constitutive activator of p38, stimulated the expression of atrial natriuretic factor (ANF), which is a genetic marker of in vivo cardiac hypertrophy. Activation of p38 was required for ANF expression induced by the hypertrophic agonists. Furthermore, a specific p38 inhibitor, SB202190, significantly changed hypertrophic morphology induced by the agonists. Surprisingly, activation of JNK led to inhibition of ANF expression induced by MEK kinase 1 (MEKK1) and the hypertrophic agonists. MEKK1-induced ANF expression was also negatively regulated by expression of c-Jun. Our results demonstrate that p38 mediates, but JNK suppresses, the development of myocyte hypertrophy.

    INTRODUCTION
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

Cardiac hypertrophy is an adaptive physiological process (49). In response to various extracellular stimuli, myocardium adapts to increased workloads through the hypertrophy of individual terminally differentiated myocytes (6, 52). The hypertrophic response is characterized by an enlargement of individual cells, an increase in the content of contractile proteins such as myosin heavy chain (MHC), and expression of embryonic genes like that for atrial natriuretic factor (ANF) (6). The hypertrophic response is compensatory in nature, but sustained excessive workloads may lead to heart failure (52).

An important question in studying cardiac hypertrophy is how extracellular signals are transmitted into myocytes to induce the hypertrophic response. It has been shown that the proto-oncogene Ha-Ras, the Galpha q-containing heterotrimeric G protein, and the interleukin-6 (IL-6) receptor gp130 are critical mediators in the hypertrophic response in vitro and in vivo (22, 26, 35), through activation of their downstream signaling pathways, such as mitogen-activated protein (MAP) kinase pathways.

MAP kinase is an essential part of cell signal transduction machinery and occupies a central position in cell growth, differentiation, and transformation (44). Several mammalian MAP kinases have been identified, including extracellular signal-regulated protein kinase (ERK) (4), c-Jun N-terminal protein kinase (JNK) (also known as SAPK, for stress-activated protein kinase) (12, 21, 34), and p38 (also known as Mkp2/CBSP) (19, 37, 59). The ERK pathway consists of Ha-Ras, Raf-1, MEK, and ERK (10, 11, 24, 31, 61, 73). ERK activity can be stimulated by a variety of extracellular stimuli and oncogenes (7). ERK in turn activates several cellular protein kinases (ribosomal S6 kinase, MAP kinase-activated protein kinase 2 [MAPAPK2], and MNK1) and nuclear transcription factor Elk (5, 14, 55, 64). Activation of the ERK pathway was shown to be necessary and sufficient to induce transformation in NIH 3T3 fibroblasts and to induce differentiation in PC12 chromocytoma cells (9, 42). The JNK pathway is composed of Ha-Ras, Rac/Cdc42Hs, MEKK, JNK kinase [JNKK], and JNK (8, 13, 23, 30, 36, 38, 41, 47, 48, 53, 60, 70). JNK is activated by various stimuli, including growth factors, cytokines, UV light irradiation, and oncogenes (29). Stimulation of JNK activity results in activation of several transcription factors such as c-Jun, ATF2, Elk, and Sap-1 (12, 18, 21, 28, 55, 72). The biological functions of the JNK pathway, however, remain to be elucidated. Several recent reports suggest that the JNK pathway may be involved in regulation of programmed cell death (apoptosis), but its precise role in apoptosis remains controversial (17, 40, 50, 74, 77). The signaling pathway that leads to p38 activation is still incomplete. The MAP kinase kinases (MKKs) for p38 are JNKK1, MKK3, and MKK6, and the MKK kinases may include Tak1 and Ask1 (20, 27, 39, 56, 75). p38 can be activated by proinflammatory cytokines such as IL-1 and tumor necrosis factor (TNF) and by environmental stresses such as UV irradiation and osmotic pressures (19, 37, 59). The biological functions of p38 have yet to be determined.

The role(s) of MAP kinase pathways in the development of the hypertrophic response has been studied extensively but is still far from conclusive. ERK can be activated by hypertrophic agonists such as endothelin-1 (ET-1), phenylephrine (PE), and angiotensin II in a Ha-Ras- and Raf-1-dependent manner (3, 54, 65, 67, 76). But the role played by the ERK pathway in the hypertrophic response is controversial. It was reported that ANF expression was stimulated by activated mutants of Raf-1, Raf-1(B × B), and MEK1, MEK1(Delta NED) (16, 67), suggesting that the ERK pathway is required for mediating the hypertrophic response. On the other hand, it was found that ANF expression was blocked by MEK1(Delta NED) and by the activation of ERK and was unaffected by a specific MEK1 inhibitor, PD098059 (54, 68, 69). In Ras transgenic mice, it was also found that ERK activation was not involved in the development of the hypertrophic response, including ANF expression (57). It is agreed, in general, that ERK activation is insufficient for transcriptional activation of the ANF gene (54, 57, 69).

Hypertrophic agonists such as PE also stimulated JNK activity (57, 69). In addition, MEKK1, the MKK kinase for JNK, was able to stimulate ANF expression (57, 69). But it is not clear whether activation of JNK is necessary and/or sufficient for the development of myocyte hypertrophy.

Here we show that p38 activity was stimulated by and required for ANF expression by hypertrophic agonists like ET-1, PE, and leukemia inhibitory factor (LIF) in rat neonatal ventricular myocytes. Activation of p38 by itself was also sufficient to stimulate ANF expression. In addition, the specific p38 inhibitor SB202190 significantly changed the hypertrophic morphology induced by ET-1 and LIF. In contrast, activation of JNK inhibited ANF expression induced by MEKK1 and the hypertrophic agonists. Our results demonstrate that p38 and JNK had opposing effects on the development of myocyte hypertrophy.

    MATERIALS AND METHODS
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

Cell cultures. Rat neonatal ventricular myocytes (referred to hereafter in this work as myocytes, for simplicity) were prepared from the hearts of 1- to 3-day-old Sprague-Dawley rats, as described previously (62). Ventricles were separated from atrial tissue and washed briefly in digestion solution (116 mM NaCl, 20 mM HEPES, 1 mM NaH2PO4, 5.5 mM glucose, 5.4 mM KCl, 0.8 mM MgSO4 [pH 7.35], collagenase [95 U/ml], and pancreatin [0.6 mg/ml]). The myocytes were dissociated in fresh digestion buffer and collected by centrifugation. The isolated cells, which were a mixture of myocytes and nonmyocyte fibroblasts, were suspended in plating media (Dulbecco's modified Eagle's medium and medium 199 at a ratio of 4:1) and plated onto 150-mm-diameter noncoated culture dishes for 1 h to reduce contaminated cardiac fibroblasts, which often constitute 5% of the cardiac cells and can attach to noncoated culture dishes. After a 1-h incubation, unattached cells were collected and more than 95% of the cells were myocytes as determined by cell morphology and myosin staining. Myocytes were purified by Percoll gradient, replated at a density of 1.5 × 105 in plates precoated with 1% gelatin or 1 × 105 in 25-mm-diameter etched coverslips and grown in plating media. After 24 h, the media were replaced by serum-free media (DMEM and medium 199; 4:1), supplemented with 2 mM glutamine, penicillin (100 U/ml), and 100 streptomycin (100 mg/ml).

cDNA constructs. Expression vectors of MEKKDelta , JNK1, JNK1(APF), JNKK1, JNKK1(AA), p38, p38(Yright-arrowF), MKK6b, MKK6b(EE), c-Jun, c-Jun(A63), GAL4-c-Jun, GAL4-c-Jun(AA63/73), GAL4-Elk, and GAL4-Elk (AA383/389) have been described elsewhere (19, 20, 21, 25, 39, 41, 54). Reporter genes of ANF-luciferase (ANF-Luc), in which the full-length rat ANF promoter (at position -3003) was fused to firefly luciferase gene, and 5×GAL4-Luc, in which the GAL4 DNA-binding domain was fused to the luciferase gene, have also been described previously (39, 41, 62).

Fusion proteins. Glutathione-S-transferase (GST)-c-Jun, GST-ATF2, and GST-hsp27 were purified on glutathione-agarose, as described previously (39, 48).

Transfections. Myocytes were transiently transfected with mammalian expression vectors encoding p38, p38(Yright-arrowF), MKK6b, MKK6b(EE), MEKKDelta , JNK1, JNK1(APF), JNKK1, JNKK1(AA), c-Jun, c-Jun(A63), GAL4-c-Jun, GAL4-c-Jun(AA63/73), GAL4-Elk, GAL4-Elk(AA383/389), and appropriate luciferase reporter genes by using Tfx-20 (Promega), according to the manufacturer's procedure. After transfection, cells were washed three times and maintained in serum-free medium with or without ET-1 (10 nM), PE (50 µM), and LIF (1 nM) in the absence or presence of specific p38 inhibitor SB202190 (20 µM), or the specific MEK1 inhibitor PD098059 (50 µM) for 48 h. Luciferase assays were performed as described before (39).

Immunofluorescence staining. Purified cardiac myocytes (104 cells/cm2) were cultured in serum-free medium in the presence or absence of 10 nM ET-1 or 1 nM LIF and in the presence or absence of the specific p38 inhibitor SB202190 (10 µM) for 4 days. The cells were then washed with phosphate-buffered saline, fixed with 4% paraformaldehyde for 30 min at 25°C, and washed three times. Immunostaining was performed as described previously (62). Anti-alpha -MHC monoclonal antibody (a gift from Jim Lin, University of Iowa, Iowa City) was used to identify cardiac myocytes.

Kinase assays. JNK, p38, ERK, and MAPKAPK2 assays were performed as described previously (39, 41, 59). Briefly, myocytes were serum starved for 24 h and then treated with or without agonists for various times as indicated in the figure legends. The cells were harvested in lysis buffer and clarified by centrifugation. Endogenous JNK, p38, ERK, and MAPKAPK2 were immunoprecipitated with their specific antibodies for 3 h at 4°C. The activity of the immune complex was assayed at 30°C for 30 min in 30 µl of kinase buffer (39) in the presence of 10 µM ATP-10 µCi of [gamma -32P]ATP (10 Ci/mmol) with appropriate substrates, as indicated in the figure legends. The reactions were terminated with Laemmli sample buffer. The proteins were resolved by sodium dodecyl sulfate-13% polyacrylamide gel electrophoresis followed by autoradiography. The phosphorylated proteins were quantitated by a PhosphoImager.

    RESULTS
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

Activation of p38 kinase activity in myocytes. p38 can be activated by various extracellular stimuli, including proinflammatory cytokines IL-1 and TNF, and environmental stress, such as UV irradiation (1, 19, 37, 59). Since the hypertrophic response in myocytes is a unique type of cellular stress response (1, 51), we tested whether hypertrophic agonists can also stimulate p38 activity in myocytes.

Myocytes were isolated and grown in serum-free media for 24 h as described previously (62). The cells were treated with ET-1 and PE for various times as indicated (Fig. 1A). Endogenous p38 was immunoprecipitated with anti-p38 antibody (PharMingen, Inc.) and its activity was measured in immune complex kinase assays with GST-ATF2 as a substrate, as described previously (41, 47). We found that p38 activity was significantly stimulated by ET-1 and PE, and the stimulation lasted a few hours (Fig. 1A). p38 activity was also mildly stimulated by LIF (data not shown). This result demonstrates that p38 activity can also be stimulated by stimuli that induce myocyte hypertrophy.


View larger version (40K):
[in this window]
[in a new window]
  		FIG. 1.   Activation of p38, JNK, and ERK in myocytes. (A) Myocytes were grown in serum-free medium for 24 h and then treated with ET-1 (10 nM) or PE (50 µM) for the indicated times or left untreated. The cells were harvested after stimulation, and whole-cell extracts were prepared. Endogenous p38 was immunoprecipitated from cell extracts (30 µg) with anti-p38 antibody, and its activity was measured in immune complex kinase assays with GST-ATF2 (2 µg) as a substrate. (B) Endogenous JNK was immunoprecipitated from cell extracts (30 µg) with anti-JNK1 antibody, and its activity was measured in immune complex kinase assays with GST-c-Jun (2 µg) as a substrate. (C) Endogenous ERK was immunoprecipitated from cell extracts (30 µg) with anti-ERK antibody, and its activity was measured in immune complex kinase assays with MBP (4 µg) as a substrate. For all panels, fold stimulation is indicated below each lane.

We also examined the regulation of JNK and ERK activities in myocytes by ET-1 and PE. Endogenous JNK was immunoprecipitated with anti-JNK antibody (PharMingen, Inc.) and its activity was measured in immune complex kinase assays with GST-c-Jun as a substrate, as described previously (39, 41). Like p38, JNK activity was stimulated by ET-1 and PE and the activation lasted a few hours (Fig. 1B). JNK activity was also mildly stimulated by LIF (data not shown). This result is consistent with and reinforces earlier reports that PE was able to stimulate JNK activity in myocytes (57, 69).

In contrast, endogenous ERK activity was stimulated by ET-1 and PE transiently, as measured by immune complex kinase assays using anti-ERK antibody (Upstate Biotechnology Inc.) with MBP (myelin basic protein) as a substrate (Fig. 1C), in agreement with an earlier report (3).

Activation of p38 results in stimulation of transcription factor Elk activity in myocytes. In several cell systems, p38 activity can be stimulated by coexpression of p38 with MKK6b, or by expression of constitutively activated MKK6b(EE), in which the activating phosphorylation residues Ser207 and Thr211 were replaced by glutamic acids (25). The activation of p38 leads to the stimulation of transcription factor Elk activity (56). Using transcription assays, we tested whether the activation of p38 can lead to the stimulation of Elk activity in myocytes.

Myocytes were transfected with expression vectors of p38, MKK6b, or MKK6b(EE) or empty vector, along with a GAL4-Elk fusion protein, in which the Elk transactivation domain was fused to the GAL4 DNA-binding domain (43). Expression of MKK6b(EE), or coexpression of p38 with MKK6b stimulated GAL4-Elk activity manyfold, as measured by a 5×GAL4-Luc reporter gene (Fig. 2A). In contrast, coexpression of p38 with MKK6b did not stimulate the activity of the GAL4-Elk(AA383/389) mutant, in which both p38 phosphorylation residues Ser383 and Ser389 were replaced with alanines (Fig. 2A). The stimulation of GAL4-Elk activity is dependent on p38 activation, since it was inhibited by the specific p38 inhibitor SB202190 (Fig. 2A). Coexpression of p38 and MKK6b also stimulated p38 kinase activity, as measured in immune complex kinase assays with GST-ATF2 as a substrate (Fig. 2B). These results demonstrate that activation of p38 is sufficient to stimulate its reporter gene expression in myocytes.


View larger version (22K):
[in this window]
[in a new window]
  		FIG. 2.   Activation of p38 stimulates gene transcription in myocytes. (A) Myocytes were cotransfected with a 5×GAL4-Luc reporter plasmid (1 µg/plate) and expression vectors encoding p38, MKK6b, and/or MKK6b(EE) (300 ng each) and/or GAL4-Elk or GAL4-Elk(Ala383/389) (10 ng each) in the presence (+) or absence of the specific p38 inhibitor SB202190 (20 µM) as indicated. After 48 h, cells were harvested, and luciferase activity was determined and normalized to the protein content of each extract. Luciferase activity expressed by cells transfected with pSRalpha was given an arbitrary value of 1. The results are presented as means ± standard errors (error bars) and represent six individual experiments. (B) Myocytes were transfected with expression vectors encoding MKK6b, M2-Flag-tagged p38, or empty vector (3 µg each) as indicated. M2-p38 was immunoprecipitated with anti-M2 antibody (Kodak Inc.), and its activity was measured as described in the legend to Fig. 1A.

Activation of p38 by itself is sufficient to induce ANF expression. ANF expression is an important genetic marker of cardiac hypertrophy in vitro and in vivo (6). To determine the effect of p38 activation on ANF expression, we tested whether p38 activation was able to stimulate ANF promoter activity.

Myocytes were transfected with an ANF-Luc reporter gene along with expression vectors encoding MKK6b(EE) or empty vector. Expression of MKK6b(EE) stimulated ANF-Luc activity manyfold (Fig. 3), yet this result does not rule out the possibility that MKK6b(EE) may stimulate ANF expression in a p38-independent manner, as it does in the induction of T-lymphocyte apoptosis (25). Therefore, we tested whether MKK6b(EE)-induced ANF expression is due to activation of p38.


View larger version (17K):
[in this window]
[in a new window]
  		FIG. 3.   Activation of p38 by itself is sufficient to stimulate ANF expression in myocytes. Myocytes were cotransfected with the ANF-Luc reporter plasmid (1.5 µg/plate) and expression vectors encoding p38, p38(Yright-arrowF), MKK6b, and/or MKK6b(EE) (300 ng each), in the presence (+) or absence of the specific p38 inhibitor SB202190 (20 µM) as indicated. After 48 h, the cells were harvested and luciferase activity was determined and normalized to the protein content of each extract. Luciferase activity expressed by cells transfected with pSRalpha was given an arbitrary value of 1. The results are presented as means ± standard errors (error bars) and represent six individual experiments.

Myocytes were transfected with the ANF-Luc reporter gene along with expression vectors encoding p38, MKK6b, or empty vector. Expression of p38 or MKK6b alone was able to stimulate ANF-Luc activity mildly (Fig. 3). Coexpression of p38 and MKK6b together stimulated ANF-Luc activity manyfold (Fig. 3). The effect of MKK6b is dependent on p38 activation, since MKK6b failed to stimulate ANF-Luc activity when it was cotransfected with an inactive p38(Yright-arrowF) mutant, in which one of the activating phosphorylation residues, Tyr182, was replaced by phenylalanine (Fig. 3). Furthermore, the specific p38 inhibitor SB202190 completely blocked the effect of p38/MKK6b and MKK6b(EE) (Fig. 3). The inhibition was specific, since the dose response of ANF promoter inhibition was well correlated with the dose response of p38 inhibition to SB202190 (data not shown). These results demonstrate that activation of p38 by itself is sufficient to stimulate ANF expression.

p38 is required for stimulation of ANF expression by hypertrophic agonists. It is known that ET-1 and PE can induce expression of ANF in myocytes (6). Here we show that they also stimulate p38 activity (Fig. 1A) and that p38 activation by itself was sufficient to stimulate ANF promoter activity (Fig. 3). Therefore, we tested whether activation of p38 is required for ANF expression induced by these agonists.

Myocytes were cotransfected with the ANF-Luc reporter gene, along with expression vectors of p38, MKK6b, or empty vector. The cells were then treated with or without the hypertrophic agonists, as indicated (Fig. 4). Treatment with ET-1 increased ANF-Luc activity sevenfold (Fig. 4A). Coexpression of p38 with MKK6b potentiated the effect of ET-1, leading to 110-fold activation (Fig. 4A). The potentiation by p38/MKK6b was shown in a synergistic manner, since coexpression of p38 with MKK6b caused only a 60-fold activation (Fig. 4A). However, p38 may act in a parallel but separate signaling pathway from the ET-1 signaling pathway, leading to stimulation of ANF-Luc activity. Therefore, we examined whether the specific p38 inhibitor SB202190 can inhibit ET-1-induced ANF expression. Treatment of myocytes with SB202190 completely inhibited the stimulation of ANF-Luc activity by ET-1 (Fig. 4A), suggesting that p38 acts downstream of ET-1. The mechanism of potentiation is likely due to posttranslational modification of p38 and MKK6, since ET-1 stimulated p38 activity (Fig. 1A) but did not significantly affect p38 expression (data not shown).


View larger version (15K):
[in this window]
[in a new window]
 

View larger version (9K):
[in this window]
[in a new window]
 

View larger version (16K):
[in this window]
[in a new window]
  		FIG. 4.   p38 mediates the stimulatory effects of ET-1, PE, and LIF on ANF expression in myocytes. Myocytes were transfected with the ANF-Luc reporter plasmid (1.5 µg/plate) and expression vectors encoding p38 and MKK6b (300 ng each). The cells were treated with hypertrophic agonists ET-1 (10 nM) (A), PE (50 µM) (B), or LIF (1 nM) (C), in the presence (+) or absence of the specific p38 inhibitor SB202190 (20 µM), as indicated. The ANF-Luc activity was determined as described in the legend to Fig. 3. The results are presented as means ± standard errors (error bars) and represent six individual experiments.

In parallel experiments, coexpression of p38 with MKK6b also potentiated the stimulation of ANF-Luc activity by PE and LIF (Fig. 4B and C), and this stimulation was also blocked by the specific p38 inhibitor SB202190 (Fig. 4B and C). These results demonstrate that the p38 pathway is one of the signaling pathways that mediate the effects of hypertrophic agonists on ANF expression.

Inhibition of p38 activity changes the hypertrophic morphology of myocytes. Myocytes were treated with or without ET-1 and LIF in the presence or absence of the specific p38 inhibitor SB202190 or the specific MEK1 inhibitor PD098059 as indicated (Fig. 5). The morphologic changes were examined by immunostaining, as described previously (38, 62). Treatment of myocytes with ET-1 or LIF led to an increase in cell size and the accumulation and assembly of individual MHC into organized sarcomeric units (Fig. 5D and G). The specific p38 inhibitor SB202190 significantly changed the hypertrophic morphology induced by ET-1 and LIF; the cells became thinner and more elongated instead of enlarged, and the assembly of myofilament appears in much disarray (Fig. 5F and I). The specific p38 inhibitor SB202190 also changed PE-induced hypertrophic morphology (data not shown). In contrast, the specific MEK1 inhibitor PD098059 had no significant effect on the hypertrophic morphology induced by ET-1 and LIF (Fig. 5E and H), in agreement with an earlier report (66). This data indicates that p38 activation may also be involved in the hypertrophic morphology changes.


View larger version (103K):
[in this window]
[in a new window]
  		FIG. 5.   Inhibition of p38 activity changes the hypertrophic morphology induced by ET-1 and LIF in myocytes. Myocytes were either left untreated (A to C) or were treated with ET-1 (10 nM) (D to F) or LIF (1 nM) (G to I), in the presence or absence (-) of the specific MEK1 inhibitor PD098059 (50 µM) (B, E, and H) or the specific p38 inhibitor SB202190 (10 µM) (C, F, and I), as indicated. After 48 h, the cells were stained with anti-alpha -MHC monoclonal antibody, followed by fluorescein isothiocyanate-conjugated anti-mouse immunoglobulin (green). ANF polyclonal antibody was recognized by rhodamine-conjugated anti-rabbit immunoglobulin G (orange).

Activation of JNK blocks ANF expression induced by MEKK1 and the hypertrophic agonists. The fact that JNK can be activated by hypertrophic agonists (Fig. 1B) suggests that the JNK pathway is involved in the hypertrophic response. We tested this possibility by using MEKKDelta , an NH2-terminal truncated version of MEKK1 which functions as a constitutive activator of JNK (48), since there is no known constitutively active JNK or JNKK (37a).

We examined whether MEKKDelta was able to stimulate c-Jun transcription activity in myocytes, as it does in other cells (39, 41). Myocytes were cotransfected with expression vectors encoding MEKKDelta , JNK1, JNK1(APF), or empty vector along with a GAL4-c-Jun fusion protein, which consists of the GAL4 DNA binding domain and the c-Jun transactivation domain (Fig. 6). JNK1(APF) is a kinase-deficient mutant, in which the activating phosphorylation residues Thr183 and Tyr185 were replaced by alanine and phenylalanine, respectively (12, 41). Expression of MEKKDelta -stimulated GAL4-c-Jun transcription activity manyfold, as measured by the GAL4-Luc reporter gene (Fig. 6). As expected, the effect of MEKKDelta was potentiated by cotransfected wild-type JNK1 and inhibited by the inactive JNK1(APF) mutant, indicating that MEKK stimulates c-Jun transcription activity in a JNK-dependent manner in myocytes. The effect of JNK1 on MEKKDelta -induced GAL-4-c-Jun-driven expression appeared to be biphasic. In small amounts (10 to 150 ng), JNK1 potentiated the effect of MEKKDelta on GAL4-c-Jun-driven expression. However, in larger amounts (300 ng), JNK1 failed to continue to potentiate the effect of MEKKDelta .


View larger version (15K):
[in this window]
[in a new window]
  		FIG. 6.   Stimulation of c-Jun transcription activity by MEKK1 in myocytes is through the JNK pathway. Myocytes were transfected with the 5×GAL4-Luc reporter plasmid (1 µg/plate), GAL4-c-Jun or GAL4-c-Jun(Ala63/73) (10 ng each), and expression vector encoding MEKKDelta (10 ng) or JNK1 or JNK1 (APF) (amounts as shown) as indicated. The GAL4-Luc activity was determined as described in the legend to Fig. 2. The results are presented as means ± standard errors (error bars) and represent six individual experiments, except that the data on 300 ng of JNK1 represent three individual experiments.

Then, we examined the effect of MEKKDelta on ANF expression in myocytes by measuring ANF promoter activity. Expression of MEKKDelta stimulated ANF expression manyfold, as measured by ANF-Luc activity (Fig. 7A), in agreement with earlier reports (57, 69). However, this result does not rule out the possibility that MEKKDelta can stimulate ANF expression in a JNK-independent manner, as it does in the induction of c-myc and Sap-1 (29, 72). Therefore, we tested whether the effect of MEKK is due to the activation of JNK.


View larger version (17K):
[in this window]
[in a new window]
 

View larger version (20K):
[in this window]
[in a new window]
 

View larger version (17K):
[in this window]
[in a new window]
  		FIG. 7.   Activation of JNK inhibits MEKK1-induced ANF expression. (A) Myocytes were transfected with the ANF-Luc reporter plasmid (1.5 µg/plate) and expression vector encoding MEKKDelta (10 ng) or JNK1 or JNK1 (APF) (amounts as shown) as indicated. (B) Myocytes were transfected with an ANF-Luc reporter plasmid (1.5 µg/plate) and expression vectors encoding MEKKDelta (10 ng) and/or JNKK1 or JNKK1 (AA) (amounts as shown) as indicated. The results are presented as means ± standard errors (error bars) and represent six individual experiments. (C) Myocytes were transfected with the ANF-Luc reporter plasmid (1.5 µg/plate) and expression vectors encoding MEKKDelta (10 ng) and/or c-Jun or c-Jun (A63) (amounts as shown), or empty vector as indicated. The results are presented as means ± standard errors (error bars) and represent three individual experiments. For all panels, the ANF-Luc activity was measured as described in the legend to Fig. 3.

Myocytes were transfected with the ANF-Luc reporter gene, along with expression vectors encoding MEKKDelta , JNK1, JNK1(APF), JNKK1, JNKK1(AA), or empty vector. The JNKK1(AA) mutant is an interfering mutant, in which the activating phosphorylation residues Ser257 and Thr261 were replaced with alanines (39, 41). Surprisingly, we found that the effect of MEKKDelta on ANF expression was inhibited, rather than potentiated, by cotransfected wild-type JNK1 (Fig. 7A). Conversely, the effect of MEKKDelta was potentiated by the inactive JNK1(APF) mutant (Fig. 7A). The effect of MEKKDelta was also inhibited by wild-type JNKK1 and potentiated by the inactive JNKK1(AA) mutant (Fig. 7B). Both inhibition and potentiation are shown in a dose-dependent manner (Fig. 7A and B). Interestingly, the effect of wild-type JNK1 (and JNKK1) on MEKKDelta -induced ANF expression also appeared to be biphasic. In small amounts (10 to 150 ng), JNK1 (and JNKK1) inhibited the MEKKDelta effect. But in larger amounts (300 ng), JNK1 (JNKK1) failed to continue to suppress the MEKKDelta effect.

The inhibitory effect of JNK on MEKKDelta -induced ANF expression appears to be mediated by c-Jun. As shown in Fig. 7C, coexpression of c-Jun resulted in suppression of MEKKDelta -induced ANF expression in a dose-dependent manner. Taken together, these results indicate that stimulation of ANF expression by MEKKDelta is independent of JNK. In fact, activation of the JNK pathway negatively regulated MEKKDelta -induced ANF expression.

Consistent with the findings above, JNK also negatively regulated ANF expression induced by hypertrophic agonists like ET-1, PE, and LIF. Transfection of wild-type JNK1 inhibited the ANF expression (Fig. 8). Conversely, transfection of the inactive JNK1(APF) mutant potentiated the ANF expression (Fig. 8).


View larger version (21K):
[in this window]
[in a new window]
  		FIG. 8.   Activation of JNK inhibits ANF expression induced by ET-1, PE, and LIF. Myocytes were transfected with the ANF-Luc reporter plasmid (1.5 µg/plate) and expression vectors encoding JNK1 or JNK1 (APF) (150 ng each). The cells were left untreated or were treated with the hypertrophic agonists as indicated. The ANF-Luc activity was measured as described in the legend to Fig. 3. The results are presented as means ± standard errors (error bars) and represent six individual experiments.

    DISCUSSION
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

In this report we demonstrate that JNK and p38 MAP kinases have opposing effects on cardiomyocyte hypertrophy. Activation of p38 is necessary and sufficient for ANF expression and is probably involved in the induction of the hypertrophic morphology changes. On the other hand, activation of JNK suppresses ANF expression induced by MEKK1 and hypertrophic stimuli such as PE and ET-1.

The conclusion that the p38 pathway may be required for the development of myocyte hypertrophy is based on the following four lines of evidence.

First, p38 activity was stimulated by hypertrophic agonists, such as ET-1 and PE (Fig. 1A). The fact that activation of p38 lasted a few hours suggests that it is a relevant event in the development of myocyte hypertrophy. This is in agreement with an earlier report that in vivo, p38 was activated by ischemia and/or reperfusion in isolated rat hearts (2). In contrast, the activation of ERK was transient (Fig. 1C), in agreement with the previous report that the ERK pathway may not be directly involved in the hypertrophic response (54).

Second, expression of MKK6b(EE), the constitutive activator of p38, stimulated ANF expression (Fig. 3). The effect of MKK6b(EE) was dependent on activation of p38, since coexpression of MKK6b with p38, but not the inactive p38(Yright-arrowF) mutant, stimulated ANF expression (Fig. 3). This result was further supported by the finding that the specific p38 inhibitor SB202190 completely blocked the effect of MKK6b (Fig. 3).

Third, p38 was required for the induction of ANF expression by the hypertrophic agonists, including ET-1, PE, and LIF, though it remains to be determined whether p38 is also required for the development of other forms of myocyte hypertrophy. The effects of the hypertrophic agonists were potentiated by coexpression of p38 with MKK6b, and blocked by the specific p38 inhibitor SB202190 (Fig. 4). In myocytes, both ET-1 and PE induce ANF expression and secretion through yet-to-be defined signaling pathways which involve G proteins (Galpha q and Galpha i) (32, 46, 63). The identification of p38 as a signaling mediator that acts downstream of ET-1 and PE provides a model system for further elucidation of ET-1 and PE signaling pathways. LIF is a member of the IL-6 family of cytokines and exerts its biological effects through binding to the heterodimers formed between its receptor and gp130 (22). It was reported that the Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling pathway may act downstream of LIF to induce the hypertrophic response in myocytes (62). It will be of interest to determine the possible interplay between the p38 pathway and the JAK/STAT pathway in regard to the development of myocyte hypertrophy.

Fourth, the specific p38 inhibitor SB202190 significantly changed the hypertrophic morphology induced by ET-1 and LIF in myocytes (Fig. 5). This result suggests that p38 not only is required for expression of ANF but also may be involved in the hypertrophic morphology changes. This finding is of particular interest since little is known about signaling pathways that mediate the morphology changes induced by hypertrophic agonists. It is not known how p38 influences the hypertrophic morphology changes. Some candidates that may be involved are Rac and Cdc42Hs. We and others have found that p38 can be activated by the oncoproteins Rac and Cdc42Hs (33, 58), both of which are important mediators in actin reorganization in many other cell systems (58). Rac and Cdc42Hs also stimulated ANF expression in myocytes (49a). It remains to be demonstrated whether Rac and Cdc42Hs are also involved in the hypertrophic morphology changes, and whether their effects are dependent on p38 activation.

Our conclusion is further supported by recent reports that hypertrophic morphology changes and the expression of ANF gene were induced by recombinant adenoviruses of constitutively active MKK6(EE) and suppressed by the specific p38 inhibitor SB202190 (71, 78). The mechanisms by which p38 mediates myocyte hypertrophy are currently under investigation.

The role of the JNK pathway in the development of myocyte hypertrophy is complicated. Like p38, JNK activity was stimulated by hypertrophic agonists, including ET-1 and PE (Fig. 1B). Expression of a small amount (10 ng) of JNK activator, MEKKDelta , was sufficient to induce ANF expression (Fig. 7). These results are in agreement with previous reports (57, 69), suggesting that the JNK pathway is required for the development of myocyte hypertrophy. Surprisingly, we found that MEKKDelta -induced ANF expression was not dependent on JNK activation, since it was blocked by coexpression of wild-type JNK1 but potentiated by the inactive JNK1(APF) mutant (Fig. 7A). On the other hand, stimulation of c-Jun transcription activity by MEKK was dependent on JNK activation (Fig. 6).

The inhibitory effect of JNK1 on MEKKDelta -induced ANF expression appears to be mediated by c-Jun, because coexpression of c-Jun also suppressed MEKKDelta -induced ANF expression in a dose-dependent manner (Fig. 7B). This finding is in agreement with the previous report that expression of c-Jun suppressed PE-induced ANF promoter activity and the c-Jun N-terminal transactivation domain was sufficient for this inhibition (45). Although the precise mechanisms by which c-Jun suppresses MEKKDelta -induced ANF expression remain to be determined, it is plausible that phosphorylation of c-Jun on its N-terminal transactivation domain by activated JNK is required for c-Jun to interact with yet-to-be-identified limiting cardiac cofactors, leading to inhibition of ANF expression.

JNK1 exerted opposing effects on MEKKDelta -induced GAL4-c-Jun-driven expression and ANF expression. In small amounts (10 to 150 ng), JNK1 potentiated MEKKDelta -induced GAL4-c-Jun-driven expression but suppressed MEKKDelta -induced ANF expression. However, in larger amounts (300 ng), JNK1 did not continue to potentiate MEKKDelta -induced GAL4-c-Jun-driven expression and also failed to suppress MEKKDelta -induced ANF expression. It appears that 300 ng of JNK1 failed to continue to potentiate the effect of MEKK on GAL4-c-Jun due to the "squelching" effect (15). Overexpressed JNK1 (300 ng) may titrate GAL4-c-Jun and other limiting cofactors for transcription, resulting in much less promoter-bound GAL4-c-Jun and cofactors and decreased GAL4-c-Jun-driven expression. Since 300 ng of JNK1 failed to stimulate c-Jun-driven expression, it can no longer suppress MEKKDelta -induced ANF expression (Fig. 7A).

The conclusion that activation of the JNK pathway results in inhibition of MEKK-induced ANF expression in myocytes appears to be contradictory to the earlier report that MEKK stimulates ANF expression in a JNK-dependent manner (69). We do not completely understand this discrepancy. However, it is noteworthy that in the earlier report the amount of interfering mutants of JNKK, JNK, and c-Jun employed to inhibit MEKK-induced ANF expression was quite large (3 µg of each per 35-mm-diameter plate) and that the interference was not shown to be dose dependent (69). In transcription assays, cotransfection of large amounts of expression vectors may lead to repression of ANF-Luc expression. In the same earlier report, it was also found that higher amounts of MEKK expression vector (0.5, 1, or 3 µg) caused suppression of ANF expression, though small amounts of MEKK (1, 10, or 100 ng) potentiated ANF expression (69). In the experiments described in this report, the effect of JNK (or JNKK) expression vectors was dose dependent and occurred in a range of smaller quantities of plasmid (10 to 300 ng per 21-mm-diameter plate) (Fig. 7). In addition, activation of JNK also inhibited ANF expression induced by hypertrophic agonists (Fig. 8). It is likely that activation of JNK is a cellular stress response to hypertrophic stimuli and functions as a negative feedback on ANF expression induced by MEKK or the hypertrophic agonists.

The signaling pathway that mediates the effect of MEKK1 on ANF expression remains to be determined. The effect of MEKKDelta can be blocked by the specific p38 inhibitor SB202190 and the specific MEK1 inhibitor PD098059, but there is no clear correlation between activation of p38 or ERK with the effect of MEKKDelta (49a). Further studies are needed to elucidate the mechanism of the MEKK effect on ANF expression.

JNK and p38 are usually coregulated by extracellular stimuli. It was thought that these two MAP kinases may have similar functions. Our results, for the first time, demonstrate that activation of JNK and p38 has opposing effects on an important physiological event, myocyte hypertrophy. Activation of p38 induced ANF expression and was probably involved in the hypertrophic morphology changes, while activation of JNK inhibited ANF expression. This observation may provide an opportunity to investigate how differential effects can be induced by similarly regulated protein kinases.

    ACKNOWLEDGMENTS

We thank M. Karin, J. Han, K. R. Chien, G. Johnson, M. Cobb, A. Yee, S. Pelech, and J. Lin for the different plasmids and antibodies that made this work possible. We also thank J. DiDonato and J. Frost for helpful discussions.

This work was supported by American Heart Association Scientist Development Grant 9630261N and National Institutes of Health grant CA73740 (to A.L.).

    FOOTNOTES

* Corresponding author. Mailing address: Department of Pathology, Division of Molecular and Cellular Pathology, University of Alabama at Birmingham, Volker Hall G046B, 1670 University Blvd., Birmingham, AL 35294-0019. Phone: (205) 975-9225. Fax: (205) 934-1775. E-mail: lin{at}vh.path.uab.edu.

    REFERENCES
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

1. Anversa, P., C. Beghi, Y. Kikkawa, and G. Olivetti. 1985. Myocardial response to infarction in the rat. Morphometric measurement of infarct size and myocyte cellular hypertrophy. Am. J. Pathol. 118:484-492[Abstract].
2. Bogoyevitch, M. A., J. Gillespie-Brown, A. J. Ketterman, S. J. Fuller, R. Ben-Levy, A. Ashworth, C. J. Marshall, and P. H. Sugden. 1996. Stimulation of the stress-activated mitogen-activated protein kinase subfamilies in perfused heart. p38/RK mitogen-activated protein kinases and c-Jun N-terminal kinases are activated by ischemia/reperfusion. Circ. Res. 79:162-173[Abstract/Free Full Text].
3. Bogoyevitch, M. A., P. E. Glennon, M. B. Andersson, A. Clerk, A. Lazou, C. J. Marshall, P. J. Parker, and P. H. Sugden. 1994. Endothelin-1 and fibroblast growth factors stimulate the mitogen-activated protein kinase signaling cascade in cardiac myocytes. The potential role of the cascade in the integration of two signaling pathways leading to myocyte hypertrophy. J. Biol. Chem. 269:1110-1119[Abstract/Free Full Text].
4. Boulton, T. G., G. D. Yancopoulos, J. S. Gregory, C. Slaughter, C. Moomaw, J. Hsu, and M. H. Cobb. 1990. An insulin-stimulated protein kinase similar to yeast kinases involved in cell cycle control. Science 249:64-65[Abstract/Free Full Text].
5. Chen, R.-H., C. Sarnecki, and J. Blenis. 1992. Nuclear localization and regulation of erk- and rsk-encoded protein kinases. Mol. Cell. Biol. 12:915-927[Abstract/Free Full Text].
6. Chien, K. R., K. U. Knowlton, H. Zhu, and S. Chien. 1991. Regulation of cardiac gene expression during myocardial growth and hypertrophy: molecular studies of an adaptive physiologic response. FASEB J. 5:3037-3046[Abstract].
7. Cobb, M. H., and E. J. Goldsmith. 1995. How MAP kinases are regulated. J. Biol. Chem. 270:14843-14846[Free Full Text].
8. Coso, O. A., M. Chiariello, J. C. Yu, H. Teramoto, P. Crespo, N. Xu, T. Miki, and J. S. Gutkind. 1995. The small GTP-binding proteins Rac1 and Cdc42 regulate the activity of the JNK/SAPK signaling pathway. Cell 81:1137-1146[Medline].
9. Cowley, S., H. Paterson, P. Kemp, and C. J. Marchall. 1994. Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells. Cell 77:841-852[Medline].
10. Crews, C. M., A. Alessandrini, and R. L. Erikson. 1992. The primary structure of MEK, a protein kinase that phosphorylates the ERK gene product. Science 258:478-480[Abstract/Free Full Text].
11. Dent, P., W. Haser, T. A. Haystead, L. A. Vincent, T. M. Roberts, and T. W. Sturgill. 1992. Activation of mitogen-activated protein kinase kinase by v-Raf in NIH 3T3. Science 257:1404-1407[Abstract/Free Full Text].
12. Derijard, B., M. Hibi, I. H. Wu, T. Barret, B. Su, T. Deng, M. Karin, and R. J. Davis. 1994. JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain. Cell 76:1025-1037[Medline].
13. Derijard, B., J. Raingeaud, T. Barrett, I. H. Wu, J. Han, R. J. Ulevitch, and R. J. Davis. 1995. Independent human MAP-kinase signal transduction pathways defined by MEK and MKK isoforms. Science 267:682-685[Abstract/Free Full Text].
14. Fukunaga, R., and T. Hunter. 1997. MNK1, a new MAP kinase-activated protein kinase, isolated by a novel expression screening method for identifying protein kinase substrates. EMBO J. 16:1921-1933[Medline].
15. Gill, G., and M. Ptashne. 1987. Mutants of GAL4 protein altered in an activation function. Cell 51:121-126[Medline].
16. Gillespie-Brown, J., S. J. Fuller, M. A. Bogoyevitch, S. Cowley, and P. H. Sugden. 1995. The mitogen-activated protein kinase kinase MEK1 stimulates a pattern of gene expression typical of the hypertrophic phenotype in rat ventricular cardiomyocytes. J. Biol. Chem. 270:28092-28096[Abstract/Free Full Text].
17. Goillot, E., J. Raingeaud, A. Ranger, R. I. Tepper, R. J. Davis, E. Harlow, and I. Sanchez. 1997. Mitogen-activated protein kinase-mediated Fas apoptotic signaling pathway. Proc. Natl. Acad. Sci. USA 94:3302-3307[Abstract/Free Full Text].
18. Gupta, S., D. Campbell, B. Derijard, and R. J. Davis. 1995. Transcription factor ATF2 regulation by the JNK signal transduction. Science 267:389-393[Abstract/Free Full Text].
19. Han, J., J. D. Lee, L. Bibbs, and R. J. Ulevitch. 1994. A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science 265:808-811[Abstract/Free Full Text].
20. Han, J., J.-D. Lee, Y. Jiang, Z. Li, L. Feng, and R. J. Ulevitch. 1996. Characterization of the structure and function of a novel MAP kinase kinase (MKK6). J. Biol. Chem. 271:2886-2891[Abstract/Free Full Text].
21. Hibi, M., A. Lin, T. Smeal, A. Minden, and M. Karin. 1993. Identification of an oncoprotein- and UV-responsive protein kinase that binds and potentiates the c-Jun activation domain. Genes Dev. 7:2135-2148[Abstract/Free Full Text].
22. Hirota, H., K. Yoshida, T. Kishimoto, and T. Taga. 1995. Continuous activation of gp130, a signal-transducing receptor component for interleukin 6-related cytokines, causes myocardial hypertrophy in mice. Proc. Natl. Acad. Sci. USA 92:4862-4866[Abstract/Free Full Text].
23. Holland, P. M., M. Suzanne, J. S. Campbell, S. Noselli, and J. A. Cooper. 1997. MKK7 is a stress-activated mitogen-activated protein kinase kinase functionally related to hemipterous. J. Biol. Chem. 272:24994-24998[Abstract/Free Full Text].
24. Howe, L. R., S. J. Leevers, N. Gomez, S. Nakielny, P. Cohen, and C. J. Marshall. 1992. Activation of the MAP kinase pathway by the protein kinase raf. Cell 71:335-342[Medline].
25. Huang, S., Y. Jiang, Z. Li, E. Nishida, P. Mathias, S. Lin, R. J. Ulevitch, G. R. Nemerow, and J. Han. 1997. Apoptosis signaling pathway in T cells is composed of ICE/Ced-3 family proteases and MAP kinase kinase 6b. Immunity 6:739-749[Medline].
26. Hunter, J. J., N. Tanaka, H. A. Rockman, J. Ross, Jr., and K. R. Chien. 1995. Ventricular expression of a MLC-2v-ras fusion gene induces cardiac hypertrophy and selective diastolic dysfunction in transgenic mice. J. Biol. Chem. 270:23173-23178[Abstract/Free Full Text].
27. Ichijo, H., E. Nishida, K. Irie, P. ten Dijke, M. Saitoh, T. Moriguchi, M. Takagi, K. Matsumoto, K. Miyazono, and Y. Gotoh. 1997. Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways. Science 275:90-94[Abstract/Free Full Text].
28. Janknecht, R., and T. Hunter. 1997. Convergence of MAP kinase pathways on the ternary complex factor Sap-1a. EMBO J. 16:1620-1627[Medline].
29. Johnson, N. L., A. M. Gardner, K. M. Diener, C. A. Lange-Carter, J. Gleavy, M. B. Jarpe, A. Minden, M. Karin, L. I. Zon, and G. L. Johnson. 1996. Signal transduction pathways regulated by mitogen-activated/extracellular response kinase kinase kinase induce cell death. J. Biol. Chem. 27:3229-3237.
30. Karin, M. 1995. The regulation of AP-1 activity by mitogen-activated protein kinases. J. Biol. Chem. 270:16483-16486[Free Full Text].
31. Khokhlatchev, A., S. Xu, J. English, P. Wu, E. Schaefer, and M. H. Cobb. 1997. Reconstitution of mitogen-activated protein kinase phosphorylation cascades in bacteria. Efficient synthesis of active protein kinases. J. Biol. Chem. 272:11057-11062[Abstract/Free Full Text].
32. Knowlton, K. U., M. C. Michel, M. Itani, H. E. Shubeita, K. Ishihara, J. H. Brown, and K. R. Chien. 1993. The alpha 1A-adrenergic receptor subtype mediates biochemical, molecular and morphologic features of cultured myocardial cell hypertrophy. J. Biol. Chem. 268:15374-15380[Abstract/Free Full Text].
33. Kozma, R., S. Ahmed, A. Best, and L. Lim. 1995. The Ras-related protein Cdc42Hs and bradykinin promote formation of peripheral actin microspikes and filopodia in Swiss 3T3 fibroblasts. Mol. Cell. Biol. 15:1942-1952[Abstract].
34. Kyriakis, J. M., P. Banerjee, E. Nikolakaki, E. A. Dai, T. Rubie, M. F. Ahmad, J. Avruch, and J. R. Woodgt. 1994. The stress-activated protein kinase subfamily of c-Jun kinases. Nature 369:156-160[Medline].
35. LaMorte, V. J., J. Thorburn, D. Absher, A. Spiegel, J. H. Brown, K. R. Chien, J. R. Feramisco, and K. U. Knowlton. 1994. Gq- and ras-dependent pathways mediate hypertrophy of neonatal rat ventricular myocytes following alpha 1-adrenergic stimulation. J. Biol. Chem. 269:13490-13496[Abstract/Free Full Text].
36. Lange-Carter, C. A., and G. L. Johnson. 1994. Ras-dependent growth factor regulation of MEK kinase in PC12 cells. Science 265:1458-1461[Abstract/Free Full Text].
37. Lee, J. C., J. T. Laydon, P. C. McDonnell, T. F. Gallagher, S. Kumar, D. Green, D. McNulty, M. J. Blumenthal, J. R. Heys, S. W. Landvatter, J. E. Strickler, M. M. McLaughllin, I. R. Siemens, S. M. Fisher, G. P. Livi, J. R. White, J. L. Adams, and P. R. Young. 1994. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 372:739-746[Medline].
37a. Lin, A. Unpublished results.
38. Lin, A., J. Frost, T. Deng, T. Smeal, N. Al-Alawi, U. Kikkaw, T. Hunter, D. Brenner, and M. Karin. 1992. Casein kinase II is a negative regulator of c-Jun DNA binding and AP-1 activity. Cell 70:777-789[Medline].
39. Lin, A., A. Minden, H. Martinetto, F. X. Claret, C. Lange-Carter, F. Mercurio, G. L. Johnson, and M. Karin. 1995. Identification of a dual specificity kinase that activates the Jun kinases and p38-Mpk2. Science 268:286-290[Abstract/Free Full Text].
40. Liu, Z. G., H. Hsu, D. V. Goeddel, and M. Karin. 1996. Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-kappaB activation prevents cell death. Cell 87:565-576[Medline].
41. Lu, X., S. Nemoto, and A. Lin. 1997. Identification of JNK-activating kinase 2 as an activator of JNK but not p38. J. Biol. Chem. 272:24751-24754[Abstract/Free Full Text].
42. Mansour, S. J., W. T. Matten, A. S. Hermann, J. M. Candia, S. Rong, K. Fukasawa, G. F. Vande Wound, and N. G. Ahn. 1994. Transformation of mammalian cells by constitutively active MAP kinase kinase. Science 265:966-970[Abstract/Free Full Text].
43. Marais, R., J. Wynne, and R. Treisman. 1993. The SRF accessory protein Elk-1 contains a growth factor-regulated transcriptional activation domain. Cell 73:381-393[Medline].
44. Marshall, C. J. 1994. Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell 80:179-185.
45. McBride, K., L. Robitaille, S. Tremblay, S. Argentin, and M. Nemer. 1993. fos/jun repression of cardiac-specific transcription in quiescent and growth-stimulated myocytes is targeted at a tissue-specific cis element. Mol. Cell. Biol. 13:600-612[Abstract/Free Full Text].
46. McDonough, P. M., J. H. Brown, and C. C. Glembotski. 1993. Phenylephrine and endothelin differentially stimulate cardiac PI hydrolysis and ANF expression. Am. J. Physiol. 264:625-630.
47. Minden, A., A. Lin, F. X. Claret, A. Abo, and M. Karin. 1995. Selective activation of the JNK signaling cascade and c-Jun transcriptional activity by the small GTPases Rac and Cdc42Hs. Cell 81:1147-1157[Medline].
48. Minden, A., A. Lin, M. McMahon, C. Lange-Carter, B. Derijard, R. J. Davis, G. L. Johnson, and M. Karin. 1994. Differential activation of ERK and JNK mitogen-activated protein kinases by Raf-1 and MEKK. Science 266:1719-1723[Abstract/Free Full Text].
49. Morgan, H. E., E. E. Gordon, Y. Kira, B. H. L. Chua, L. A. Russo, C. J. Peterson, P. J. McDermott, and P. A. Watson. 1987. Biochemical mechanisms of cardiac hypertrophy. Annu. Rev. Physiol. 49:533-543[Medline].
49a. Nemoto, S., and A. Lin. Unpublished results.
50. Nishina, H., K. D. Fischer, L. Radvanyi, A. Shahinian, R. Hakem, A E. Rubie, A. Bernstein, T. W. Mak, J. R. Woodgett, and J. M. Penninger. 1997. Stress-signalling kinase Sek1 protects thymocytes from apoptosis mediated by CD95 and CD3. Nature 385:350-353[Medline].
51. Olivetti, G., J. M. Capasso, L. G. Meggs, E. H. Sonnenblick, and P. Anversa. 1991. Cellular basis of chronic ventricular remodeling after myocardial infarction in rats. Circ. Res. 68:856-869[Abstract/Free Full Text].
52. Olson, E. N., and D. Srivastava. 1996. Molecular pathways controlling heart development. Science 272:671-676[Abstract].
53. Pombo, C. M., J. H. Kehrl, I. Sanchez, P. Katz, J. Avruch, L. I. Zon, J. R. Woodgett, T. Force, and J. M. Kyriakis. 1995. Activation of the SAPK pathway by the human STE20 homologue germinal centre kinase. Nature 377:750-754[Medline].
54. Post, G. R., D. Goldstein, D. J. Thuerauf, C. C. Glembotski, and J. H. Brown. 1996. Dissociation of p44 and p42 mitogen-activated protein kinase activation from receptor-induced hypertrophy in neonatal rat ventricular myocytes. J. Biol. Chem. 271:8452-8457[Abstract/Free Full Text].
55. Price, M. A., A. E. Rogers, and R. Treisman. 1995. Comparative analysis of the ternary complex factors Elk-1, SAP-1a and SAP-2 (ERP/NET). EMBO J. 14:2589-2601[Medline].
56. Raingeaud, J., A. J. Whitmarsh, T. Barrett, B. Derijard, and R. J. Davis. 1996. MKK3- and MKK6-regulated gene expression is mediated by the p38 mitogen-activated protein kinase signal transduction pathway. Mol. Cell. Biol. 16:1247-1255[Abstract].
57. Ramirez, M. T., V. P. Sah, X. L. Zhao, J. J. Hunter, K. R. Chien, and J. H. Brown. 1997. The MEKK-JNK pathway is stimulated by alpha1-adrenergic receptor and ras activation and is associated with in vitro and in vivo cardiac hypertrophy. J. Biol. Chem. 272:14057-14061[Abstract/Free Full Text].
58. Ridley, A. J., H. F. Paterson, C. L. Johnston, D. Diekmann, and A. Hall. 1992. The small GTP-binding protein rac regulates growth factor-induced membrane ruffling. Cell 70:401-410[Medline].
59. Rouse, J., P. Cohen, S. Trigon, M. Morange, A. Alonso-Llamazares, D. Zamanillo, T. Hunt, and A. R. Nebreda. 1994. A novel kinase cascade triggered by stress and heat shock that stimulates MAPKAP kinase-2 and phosphorylation of the small heat shock proteins. Cell 78:1027-1037[Medline].
60. Sanchez, I., R. T. Hughes, B. J. Mayer, K. Yee, J. R. Woodgett, J. Avruch, J. M. Kyriakis, and L. I. Zon. 1994. Role of SAPK/ERK kinase-1 in the stress-activated pathway regulating transcription factor c-Jun. Nature 372:794-798[Medline].
61. Seger, R., D. Seger, F. J. Lozeman, N. G. Ahn, L. M. Graves, J. S. Campbell, L. Ericsson, M. Harrylock, A. M. Jensen, and E. G. Krebs. 1992. Human T-cell mitogen-activated protein kinase kinases are related to yeast signal transduction kinases. J. Biol. Chem. 267:25628-25631[Abstract/Free Full Text].
62. Sheng, Z., K. Knowlton, J. Chen, M. Hoshijima, J. H. Brown, and K. R. Chien. 1997. Cardiotrophin 1 (CT-1) inhibition of cardiac myocyte apoptosis via a mitogen-activated protein kinase-dependent pathway. J. Biol. Chem. 272:5783-5791[Abstract/Free Full Text].
63. Shubeita, H. E., P. M. McDonough, A. Harris, K. U. Knowlton, C. Glembotski, J. H. Brown, and K. R. Chien. 1990. Endothelin induction of sarcomere assembly and cardiac gene expression in ventricular myocytes: a paracrine mechanism for myocardial cell hypertrophy. J. Biol. Chem. 265:20555-20562[Abstract/Free Full Text].
64. Stokoe, D., D. G. Campbell, S. Nakielny, H. Hidaka, S. J. Leevers, C. Marshall, and P. Cohen. 1992. MAPKAP kinase-2; a novel protein kinase activated by mitogen-activated protein kinase. EMBO J. 11:3985-3994[Medline].
65. Thorburn, A., J. Thorburn, S. Y. Chen, S. Powers, H. E. Shubeita, J. R. Feramisco, and K. R. Chien. 1993. HRas-dependent pathways can activate morphological and genetic markers of cardiac muscle cell hypertrophy. J. Biol. Chem. 268:2244-2249[Abstract/Free Full Text].
66. Thorburn, J., J. A. Frost, and A. Thorburn. 1994. Mitogen-activated protein kinases mediate changes in gene expression, but not cytoskeletal organization associated with cardiac muscle cell hypertrophy. J. Cell Biol. 126:1565-1572[Abstract/Free Full Text].
67. Thorburn, J., M. M. McMahon, and A. Thorburn. 1994. Raf-1 kinase activity is necessary and sufficient for gene expression changes but not sufficient for cellular morphology changes associated with cardiac myocyte hypertrophy. J. Biol. Chem. 269:30580-30586[Abstract/Free Full Text].
68. Thorburn, J., M. Carlson, S. J. Mansour, K. R. Chien, N. G. Ahn, and A. Thorburn. 1995. Inhibition of a signaling pathway in cardiac muscle cells by active mitogen-activated protein kinase kinase. Mol. Biol. Cell 6:1479-1490[Abstract].
69. Thorburn, J., S. Xu, and A. Thorburn. 1997. MAP kinase- and Rho-dependent signals interact to regulate gene expression but not actin morphology in cardiac muscle cells. EMBO J. 16:1888-1900[Medline].
70. Tournier, C., A. J. Whitmarsh, J. Cavanagh, T. Barrett, and R. J. Davis. 1997. Mitogen-activated protein kinase kinase 7 is an activator of the c-Jun NH2-terminal kinase. Proc. Natl. Acad. Sci. USA 94:7337-7342[Abstract/Free Full Text].
71. Wang, Y., S. Huang, V. P. Sah, J. Ross, Jr., J. H. Brown, J. Han, and K. R. Chien. 1998. Cardiac muscle cell hypertrophy and apoptosis induced by distinct members of the p38 mitogen-activated protein kinase family. J. Biol. Chem. 273:2161-2168[Abstract/Free Full Text].
72. Whitmarsh, A. J., P. Shore, A. D. Sharrocks, and R. J. Davis. 1995. Integration of MAP kinase signal transduction pathways at the serum response element. Science 269:403-407[Abstract/Free Full Text].
73. Wood, K. W., C. Sarnecki, T. M. Roberts, and J. Blenis. 1992. ras mediates nerve growth factor receptor modulation of three signal-transducing protein kinases: MAP kinase, Raf-1, and RSK. Cell 68:1041-1050[Medline].
74. Xia, Z., M. Dickens, J. Raingeaud, R. J. Davis, and M. E. Greenberg. 1995. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 270:1326-1331[Abstract/Free Full Text].
75. Yamaguchi, K., K. Shirakabe, H. Shibuya, K. Irie, I. Oishi, N. Ueno, T. Taniguchi, E. Nishida, and K. Matsumoto. 1995. Identification of a member of the MAPKKK family as a potential mediator of TGF-beta signal transduction. Science 270:2008-2011[Abstract/Free Full Text].
76. Yamazaki, T., I. Komuro, S. Kudoh, Y. Zou, I. Shiojima, Y. Hiroi, T. Mizuno, K. Maemura, H. Kurihara, R. Aikawa, H. Takano, and Y. Yazaki. 1996. Endothelin-1 is involved in mechanical stress-induced cardiomyocyte hypertrophy. J. Biol. Chem. 271:3221-3228[Abstract/Free Full Text].
77. Yang, X., R. Khosravi-Far, H. Y. Chang, and D. Baltimore. 1997. Daxx, a novel Fas-binding protein that activates JNK and apoptosis. Cell 89:1067-1076[Medline].
78. Zechner, D., D. J. Thuerauf, D. S. Hanford, P. M. McDonough, and C. C. Glembotski. 1997. A role for the p38 mitogen-activated protein kinase pathway in myocardial cell growth, sarcomeric organization, and cardiac-specific gene expression. J. Cell Biol. 139:115-127[Abstract/Free Full Text].

Mol Cell Biol, June 1998, p. 3518-3526, Vol. 18, No. 6
0270-7306/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Deng, L., Boujdir, M., Tremontano, A., Pincus, M. R, El-Sherif, N. (2009). A Peptide from a ras Effector-Domain Blocks ras-Dependent Cardiac Hypertrophy in Myocytes. Annals of Clinical & Laboratory Science 39: 351-360 [Abstract] [Full Text]  
  • Zeidan, A., Javadov, S., Chakrabarti, S., Karmazyn, M. (2008). Leptin-induced cardiomyocyte hypertrophy involves selective caveolae and RhoA/ROCK-dependent p38 MAPK translocation to nuclei. Cardiovasc Res 77: 64-72 [Abstract] [Full Text]  
  • Vahebi, S., Ota, A., Li, M., Warren, C. M., de Tombe, P. P., Wang, Y., Solaro, R. J. (2007). p38-MAPK Induced Dephosphorylation of {alpha}-Tropomyosin Is Associated With Depression of Myocardial Sarcomeric Tension and ATPase Activity. Circ. Res. 100: 408-415 [Abstract] [Full Text]  
  • Wall, J. A., Wei, J., Ly, M., Belmont, P., Martindale, J. J., Tran, D., Sun, J., Chen, W. J., Yu, W., Oeller, P., Briggs, S., Gustafsson, A. B., Sayen, M. R., Gottlieb, R. A., Glembotski, C. C. (2006). Alterations in oxidative phosphorylation complex proteins in the hearts of transgenic mice that overexpress the p38 MAP kinase activator, MAP kinase kinase 6. Am. J. Physiol. Heart Circ. Physiol. 291: H2462-H2472 [Abstract] [Full Text]  
  • Hilfiker-Kleiner, D., Hilfiker, A., Castellazzi, M., Wollert, K. C., Trautwein, C., Schunkert, H., Drexler, H. (2006). JunD attenuates phenylephrine-mediated cardiomyocyte hypertrophy by negatively regulating AP-1 transcriptional activity. Cardiovasc Res 71: 108-117 [Abstract] [Full Text]  
  • Qian, J.-Y., Leung, A., Harding, P., LaPointe, M. C. (2006). PGE2 stimulates human brain natriuretic peptide expression via EP4 and p42/44 MAPK. Am. J. Physiol. Heart Circ. Physiol. 290: H1740-H1746 [Abstract] [Full Text]  
  • Zhang, J., Bui, T. N., Xiang, J., Lin, A. (2006). Cyclic AMP Inhibits p38 Activation via CREB-Induced Dynein Light Chain. Mol. Cell. Biol. 26: 1223-1234 [Abstract] [Full Text]  
  • Watkins, S. J., Jonker, L., Arthur, H. M. (2006). A direct interaction between TGF{beta} activated kinase 1 and the TGF{beta} type II receptor: Implications for TGF{beta} signalling and cardiac hypertrophy. Cardiovasc Res 69: 432-439 [Abstract] [Full Text]  
  • Tang, J., Qi, X., Mercola, D., Han, J., Chen, G. (2005). Essential Role of p38{gamma} in K-Ras Transformation Independent of Phosphorylation. J. Biol. Chem. 280: 23910-23917 [Abstract] [Full Text]  
  • Mendez, M., LaPointe, M. C. (2005). PGE2-induced hypertrophy of cardiac myocytes involves EP4 receptor-dependent activation of p42/44 MAPK and EGFR transactivation. Am. J. Physiol. Heart Circ. Physiol. 288: H2111-H2117 [Abstract] [Full Text]  
  • Jeong, M. Y., Kinugawa, K., Vinson, C., Long, C. S. (2005). AFos Dissociates Cardiac Myocyte Hypertrophy and Expression of the Pathological Gene Program. Circulation 111: 1645-1651 [Abstract] [Full Text]  
  • Poizat, C., Puri, P. L., Bai, Y., Kedes, L. (2005). Phosphorylation-Dependent Degradation of p300 by Doxorubicin-Activated p38 Mitogen-Activated Protein Kinase in Cardiac Cells. Mol. Cell. Biol. 25: 2673-2687 [Abstract] [Full Text]  
  • Wong, C.-h., Mruk, D. D., Siu, M. K. Y., Cheng, C. Y. (2005). Blood-Testis Barrier Dynamics Are Regulated by {alpha}2-Macroglobulin via the c-Jun N-Terminal Protein Kinase Pathway. Endocrinology 146: 1893-1908 [Abstract] [Full Text]  
  • Martinka, P., Fielitz, J., Patzak, A., Regitz-Zagrosek, V., Persson, P. B., Stauss, H. M. (2005). Mechanisms of blood pressure variability-induced cardiac hypertrophy and dysfunction in mice with impaired baroreflex. Am. J. Physiol. Regul. Integr. Comp. Physiol. 288: R767-R776 [Abstract] [Full Text]  
  • Davis, F. J., Pillai, J. B, Gupta, M., Gupta, M. P. (2005). Concurrent opposite effects of trichostatin A, an inhibitor of histone deacetylases, on expression of {alpha}-MHC and cardiac tubulins: implication for gain in cardiac muscle contractility. Am. J. Physiol. Heart Circ. Physiol. 288: H1477-H1490 [Abstract] [Full Text]  
  • Chandrasekar, B., Mummidi, S., Claycomb, W. C., Mestril, R., Nemer, M. (2005). Interleukin-18 Is a Pro-hypertrophic Cytokine That Acts through a Phosphatidylinositol 3-Kinase-Phosphoinositide-dependent Kinase-1-Akt-GATA4 Signaling Pathway in Cardiomyocytes. J. Biol. Chem. 280: 4553-4567 [Abstract] [Full Text]  
  • Martindale, J. J., Wall, J. A., Martinez-Longoria, D. M., Aryal, P., Rockman, H. A., Guo, Y., Bolli, R., Glembotski, C. C. (2005). Overexpression of Mitogen-activated Protein Kinase Kinase 6 in the Heart Improves Functional Recovery from Ischemia in Vitro and Protects against Myocardial Infarction in Vivo. J. Biol. Chem. 280: 669-676 [Abstract] [Full Text]  
  • Nishida, K., Yamaguchi, O., Hirotani, S., Hikoso, S., Higuchi, Y., Watanabe, T., Takeda, T., Osuka, S., Morita, T., Kondoh, G., Uno, Y., Kashiwase, K., Taniike, M., Nakai, A., Matsumura, Y., Miyazaki, J.-i., Sudo, T., Hongo, K., Kusakari, Y., Kurihara, S., Chien, K. R., Takeda, J., Hori, M., Otsu, K. (2004). p38{alpha} Mitogen-Activated Protein Kinase Plays a Critical Role in Cardiomyocyte Survival but Not in Cardiac Hypertrophic Growth in Response to Pressure Overload. Mol. Cell. Biol. 24: 10611-10620 [Abstract] [Full Text]  
  • Bachetti, T., Comini, L., Pasini, E., Ferrari, R. (2004). Anti-cytokine therapy in chronic heart failure: new approaches and unmet promises. Eur Heart J Suppl 6: F16-F21 [Abstract] [Full Text]  
  • Sekiguchi, K., Li, X., Coker, M., Flesch, M., Barger, P. M, Sivasubramanian, N., Mann, D. L (2004). Cross-regulation between the renin-angiotensin system and inflammatory mediators in cardiac hypertrophy and failure. Cardiovasc Res 63: 433-442 [Abstract] [Full Text]  
  • Uddin, S., Ah-Kang, J., Ulaszek, J., Mahmud, D., Wickrema, A. (2004). Differentiation stage-specific activation of p38 mitogen-activated protein kinase isoforms in primary human erythroid cells. Proc. Natl. Acad. Sci. USA 101: 147-152 [Abstract] [Full Text]  
  • Schulz, R., Aker, S., Belosjorow, S., Konietzka, I., Rauen, U., Heusch, G. (2003). Stress kinase phosphorylation is increased in pacing-induced heart failure in rabbits. Am. J. Physiol. Heart Circ. Physiol. 285: H2084-H2090 [Abstract] [Full Text]  
  • Liao, Y., Takashima, S., Asano, Y., Asakura, M., Ogai, A., Shintani, Y., Minamino, T., Asanuma, H., Sanada, S., Kim, J., Ogita, H., Tomoike, H., Hori, M., Kitakaze, M. (2003). Activation of Adenosine A1 Receptor Attenuates Cardiac Hypertrophy and Prevents Heart Failure in Murine Left Ventricular Pressure-Overload Model. Circ. Res. 93: 759-766 [Abstract] [Full Text]  
  • Higuchi, Y., Otsu, K., Nishida, K., Hirotani, S., Nakayama, H., Yamaguchi, O., Hikoso, S., Kashiwase, K., Takeda, T., Watanabe, T., Mano, T., Matsumura, Y., Ueno, H., Hori, M. (2003). The Small GTP-binding Protein Rac1 Induces Cardiac Myocyte Hypertrophy through the Activation of Apoptosis Signal-regulating Kinase 1 and Nuclear Factor-{kappa}B. J. Biol. Chem. 278: 20770-20777 [Abstract] [Full Text]  
  • Akazawa, H., Komuro, I. (2003). Roles of Cardiac Transcription Factors in Cardiac Hypertrophy. Circ. Res. 92: 1079-1088 [Abstract] [Full Text]  
  • Pramanik, R., Qi, X., Borowicz, S., Choubey, D., Schultz, R. M., Han, J., Chen, G. (2003). p38 Isoforms Have Opposite Effects on AP-1-dependent Transcription through Regulation of c-Jun. THE DETERMINANT ROLE OF THE ISOFORMS IN THE p38 MAPK SIGNAL SPECIFICITY. J. Biol. Chem. 278: 4831-4839 [Abstract] [Full Text]  
  • Gupta, S., Purcell, N. H., Lin, A., Sen, S. (2002). Activation of nuclear factor-{kappa}B is necessary for myotrophin-induced cardiac hypertrophy. JCB 159: 1019-1028 [Abstract] [Full Text]  
  • Zobel, C., Kassiri, Z., Nguyen, T.-T. T., Meng, Y., Backx, P. H. (2002). Prevention of Hypertrophy by Overexpression of Kv4.2 in Cultured Neonatal Cardiomyocytes. Circulation 106: 2385-2391 [Abstract] [Full Text]  
  • Seo, M., Lee, Y.-I., Cho, C.-H., Bae, C.-D., Kim, I.-H., Juhnn, Y.-S. (2002). Bi-directional Regulation of UV-induced Activation of p38 Kinase and c-Jun N-terminal Kinase by G Protein beta gamma -Subunits. J. Biol. Chem. 277: 24197-24203 [Abstract] [Full Text]  
  • Post, G. R., Swiderski, C., Waldrop, B. A., Salty, L., Glembotski, C. C., Wolthuis, R. M. F., Mochizuki, N. (2002). Guanine Nucleotide Exchange Factor-like Factor (Rlf) Induces Gene Expression and Potentiates alpha 1-Adrenergic Receptor-induced Transcriptional Responses in Neonatal Rat Ventricular Myocytes. J. Biol. Chem. 277: 15286-15292 [Abstract] [Full Text]  
  • Kerkela, R., Pikkarainen, S., Majalahti-Palviainen, T., Tokola, H., Ruskoaho, H. (2002). Distinct Roles of Mitogen-activated Protein Kinase Pathways in GATA-4 Transcription Factor-mediated Regulation of B-type Natriuretic Peptide Gene. J. Biol. Chem. 277: 13752-13760 [Abstract] [Full Text]  
  • Aikawa, R., Nagai, T., Kudoh, S., Zou, Y., Tanaka, M., Tamura, M., Akazawa, H., Takano, H., Nagai, R., Komuro, I. (2002). Integrins Play a Critical Role in Mechanical Stress-Induced p38 MAPK Activation. Hypertension 39: 233-238 [Abstract] [Full Text]  
  • Hirotani, S., Otsu, K., Nishida, K., Higuchi, Y., Morita, T., Nakayama, H., Yamaguchi, O., Mano, T., Matsumura, Y., Ueno, H., Tada, M., Hori, M. (2002). Involvement of Nuclear Factor-{kappa}B and Apoptosis Signal-Regulating Kinase 1 in G-Protein-Coupled Receptor Agonist-Induced Cardiomyocyte Hypertrophy. Circulation 105: 509-515 [Abstract] [Full Text]  
  • Antos, C. L., McKinsey, T. A., Frey, N., Kutschke, W., McAnally, J., Shelton, J. M., Richardson, J. A., Hill, J. A., Olson, E. N. (2002). Activated glycogen synthase-3beta suppresses cardiac hypertrophy in vivo. Proc. Natl. Acad. Sci. USA 10.1073/pnas.231619298v1 [Abstract] [Full Text]  
  • PETRICH, B.G., LIAO, P., WANG, Y. (2002). Using a Gene-switch Transgenic Approach to Dissect Distinct Roles of MAP Kinases in Heart Failure. Cold Spring Harb Symp Quant Biol 67: 429-438 [Abstract]  
  • Tsiani, E., Lekas, P., Fantus, I. G., Dlugosz, J., Whiteside, C. (2002). High glucose-enhanced activation of mesangial cell p38 MAPK by ET-1, ANG II, and platelet-derived growth factor. Am. J. Physiol. Endocrinol. Metab. 282: E161-E169 [Abstract] [Full Text]  
  • Omura, T., Yoshiyama, M., Yoshida, K., Nakamura, Y., Kim, S., Iwao, H., Takeuchi, K., Yoshikawa, J. (2002). Dominant Negative Mutant of c-Jun Inhibits Cardiomyocyte Hypertrophy Induced by Endothelin 1 and Phenylephrine. Hypertension 39: 81-86 [Abstract] [Full Text]  
  • Charron, F., Tsimiklis, G., Arcand, M., Robitaille, L., Liang, Q., Molkentin, J. D., Meloche, S., Nemer, M. (2001). Tissue-specific GATA factors are transcriptional effectors of the small GTPase RhoA. Genes Dev. 15: 2702-2719 [Abstract] [Full Text]  
  • Lee, S. L., Simon, A. R., Wang, W. W., Fanburg, B. L. (2001). H2O2 signals 5-HT-induced ERK MAP kinase activation and mitogenesis of smooth muscle cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 281: L646-L652 [Abstract] [Full Text]  
  • Yamamoto, K., Dang, Q. N., Maeda, Y., Huang, H., Kelly, R. A., Lee, R. T. (2001). Regulation of Cardiomyocyte Mechanotransduction by the Cardiac Cycle. Circulation 103: 1459-1464 [Abstract] [Full Text]  
  • Tanaka, K., Honda, M., Takabatake, T. (2001). Redox regulation of MAPK pathways and cardiac hypertrophy in adult rat cardiac myocyte. J Am Coll Cardiol 37: 676-685 [Abstract] [Full Text]  
  • Bueno, O. F., De Windt, L. J., Lim, H. W., Tymitz, K. M., Witt, S. A., Kimball, T. R., Molkentin, J. D. (2001). The Dual-Specificity Phosphatase MKP-1 Limits the Cardiac Hypertrophic Response In Vitro and In Vivo. Circ. Res. 88: 88-96 [Abstract] [Full Text]  
  • Aihara, Y., Kurabayashi, M., Saito, Y., Ohyama, Y., Tanaka, T., Takeda, S.-i., Tomaru, K., Sekiguchi, K.-i., Arai, M., Nakamura, T., Nagai, R. (2000). Cardiac Ankyrin Repeat Protein Is a Novel Marker of Cardiac Hypertrophy : Role of M-CAT Element Within the Promoter. Hypertension 36: 48-53 [Abstract] [Full Text]  
  • Ruwhof, C., van der Laarse, A. (2000). Mechanical stress-induced cardiac hypertrophy: mechanisms and signal transduction pathways. Cardiovasc Res 47: 23-37 [Abstract] [Full Text]  
  • Morisco, C., Zebrowski, D., Condorelli, G., Tsichlis, P., Vatner, S. F., Sadoshima, J. (2000). The Akt-Glycogen Synthase Kinase 3beta Pathway Regulates Transcription of Atrial Natriuretic Factor Induced by beta -Adrenergic Receptor Stimulation in Cardiac Myocytes. J. Biol. Chem. 275: 14466-14475 [Abstract] [Full Text]  
  • De Windt, L. J., Lim, H. W., Haq, S., Force, T., Molkentin, J. D. (2000). Calcineurin Promotes Protein Kinase C and c-Jun NH2-terminal Kinase Activation in the Heart. CROSS-TALK BETWEEN CARDIAC HYPERTROPHIC SIGNALING PATHWAYS. J. Biol. Chem. 275: 13571-13579 [Abstract] [Full Text]  
  • Bogoyevitch, M. A. (2000). Signalling via stress-activated mitogen-activated protein kinases in the cardiovascular system. Cardiovasc Res 45: 826-842 [Abstract] [Full Text]  
  • Kanda, T., Kobayashi, I., Nagai, R., Entman, M. L., Gwechenberger, M., Youker, K. A., Frangogiannis, N. G., Michael, L. H., Mendoza, L. H., Smith, C. W. (2000). Cardiac Interleukin-6 in Ischemic Myocardium • Response. Circulation 101 : e86-e86 [Full Text]  
  • Oh, C.-D., Chang, S.-H., Yoon, Y.-M., Lee, S.-J., Lee, Y.-S., Kang, S.-S., Chun, J.-S. (2000). Opposing Role of Mitogen-activated Protein Kinase Subtypes, Erk-1/2 and p38, in the Regulation of Chondrogenesis of Mesenchymes. J. Biol. Chem. 275: 5613-5619 [Abstract] [Full Text]  
  • Taigen, T., De Windt, L. J., Lim, H. W., Molkentin, J. D. (2000). Targeted inhibition of calcineurin prevents agonist-induced cardiomyocyte hypertrophy. Proc. Natl. Acad. Sci. USA 97: 1196-1201 [Abstract] [Full Text]  
  • Zheng, C., Xiang, J., Hunter, T., Lin, A. (1999). The JNKK2-JNK1 Fusion Protein Acts As a Constitutively Active c-Jun Kinase That Stimulates c-Jun Transcription Activity. J. Biol. Chem. 274: 28966-28971 [Abstract] [Full Text]  
  • Hines, W. A., Thorburn, J., Thorburn, A. (1999). Cell density and contraction regulate p38 MAP kinasedependent responses in neonatal rat cardiac myocytes. Am. J. Physiol. Heart Circ. Physiol. 277: H331-H341 [Abstract] [Full Text]  
  • Olson, E. N., Molkentin, J. D. (1999). Prevention of Cardiac Hypertrophy by Calcineurin Inhibition : Hope or Hype?. Circ. Res. 84: 623-632 [Full Text]  
  • Sugden, P. H. (1999). Signaling in Myocardial Hypertrophy : Life After Calcineurin?. Circ. Res. 84: 633-646 [Full Text]  
  • Montessuit, C., Thorburn, A. (1999). Transcriptional Activation of the Glucose Transporter GLUT1 in Ventricular Cardiac Myocytes by Hypertrophic Agonists. J. Biol. Chem. 274: 9006-9012 [Abstract] [Full Text]  
  • Johnson, D. I. (1999). Cdc42: An Essential Rho-Type GTPase Controlling Eukaryotic Cell Polarity. Microbiol. Mol. Biol. Rev. 63: 54-105 [Abstract] [Full Text]  
  • Hines, W. A., Thorburn, J., Thorburn, A. (1999). A Low-Affinity Serum Response Element Allows Other Transcription Factors To Activate Inducible Gene Expression in Cardiac Myocytes. Mol. Cell. Biol. 19: 1841-1852 [Abstract] [Full Text]  
  • Chen, G., Hitomi, M., Han, J., Stacey, D. W. (2000). The p38 Pathway Provides Negative Feedback for Ras Proliferative Signaling. J. Biol. Chem. 275: 38973-38980 [Abstract] [Full Text]  
  • Hoover, H. E., Thuerauf, D. J., Martindale, J. J., Glembotski, C. C. (2000). alpha B-crystallin Gene Induction and Phosphorylation by MKK6-activated p38. A POTENTIAL ROLE FOR alpha B-CRYSTALLIN AS A TARGET OF THE p38 BRANCH OF THE CARDIAC STRESS RESPONSE. J. Biol. Chem. 275: 23825-23833 [Abstract] [Full Text]  
  • Ichida, M., Finkel, T. (2001). Ras Regulates NFAT3 Activity in Cardiac Myocytes. J. Biol. Chem. 276: 3524-3530 [Abstract] [Full Text]  
  • Awad, M. M., Enslen, H., Boylan, J. M., Davis, R. J., Gruppuso, P. A. (2000). Growth Regulation via p38 Mitogen-activated Protein Kinase in Developing Liver. J. Biol. Chem. 275: 38716-38721 [Abstract] [Full Text]  
  • Lim, H. W., New, L., Han, J., Molkentin, J. D. (2001). Calcineurin Enhances MAPK Phosphatase-1 Expression and p38 MAPK Inactivation in Cardiac Myocytes. J. Biol. Chem. 276: 15913-15919 [Abstract] [Full Text]  
  • Ng, D. C. H., Long, C. S., Bogoyevitch, M. A. (2001). A Role for the Extracellular Signal-regulated Kinase and p38 Mitogen-activated Protein Kinases in Interleukin-1beta -stimulated Delayed Signal Tranducer and Activator of Transcription 3 Activation, Atrial Natriuretic Factor Expression, and Cardiac Myocyte Morphology. J. Biol. Chem. 276: 29490-29498 [Abstract] [Full Text]  
  • Purcell, N. H., Tang, G., Yu, C., Mercurio, F., DiDonato, J. A., Lin, A. (2001). Activation of NF-kappa B is required for hypertrophic growth of primary rat neonatal ventricular cardiomyocytes. Proc. Natl. Acad. Sci. USA 98: 6668-6673 [Abstract] [Full Text]  
  • Antos, C. L., McKinsey, T. A., Frey, N., Kutschke, W., McAnally, J., Shelton, J. M., Richardson, J. A., Hill, J. A., Olson, E. N. (2002). Activated glycogen synthase-3beta suppresses cardiac hypertrophy in vivo. Proc. Natl. Acad. Sci. USA 99: 907-912 [Abstract] [Full Text]  

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nemoto, S.
Right arrow Articles by Lin, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nemoto, S.
Right arrow Articles by Lin, A.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»